The combination of XXXX and @entity786 results in a high remission rate with moderate @entity137 in low-grade @entity1893 .

@entity1 @entity137 @entity404 @entity786 @entity3118 @entity1398 @entity281 @entity1893 @entity405
We undertook a prospective study to evaluate the role of the combination of @entity3118 and @entity786 in @entity1 with low-grade @entity1893 . Twenty-seven @entity1 with low-grade @entity1893 were treated with i.v. @entity3118 (30 mg/m ) and @entity786 (250 mg/m ) on days 1-3. Cycles were given at 4-week intervals for a maximum of six courses. Fourteen @entity1 (52%) were previously untreated, 13 @entity1 (48%) had been treated with at least one chemotherapy regimen before. Of the 27 @entity1 , 11 (41%) obtained a complete and 13 (48%) a partial remission, thus the overall response rate was 89%. The remission rate in untreated @entity1 was slightly higher than in pretreated @entity1 (93 versus 85%). The @entity137 was mild, no treatment-related mortality occurred. @entity1398 was the most common side effect, grade 4 @entity1398 of rather short duration was observed in less than 7% of the cycles. At the end of the treatment, the mean @entity404 count was 155/ l and the mean @entity405 count 204/ l. @entity281 did not occur. These results show that the combination of @entity3118 and @entity786 in the doses used in this study is an effective regimen with manageable @entity137 in low-grade @entity1893 .
